Table 1.
Summary of the included studies.
| Author | Year of publication | Country | Start Time | End Time | Number of patients | Males (%) | PS (%) 0/1/2 | Median age (range) | Tumour location Head/Neck | Tumour location Body/Tail | Number of LAPC | Number of MPC | Metastasis in liver | Metastasis in lungs | Metastasis in bones | Metastasis in peritoneal | Metastasis in lymph nodes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stein27 | 2016 | USA | 2011.11 | 2014.1 | 68 | 62% | 47/53/0 | 62(46–79) | 44 | 18 | 31 | 37 | 20 | 12 | 0 | 14 | 15 |
| Vivaldi28 | 2016 | Italy | 2008 | 2014 | 137 | 48% | 67/33/0 | 60(33–75) | 73 | 62 | 56 | 81 | 64 | 14 | 4 | 26 | 0 |
| Mahaseth21 | 2013 | USA | 2010.6 | 2012.6 | 56 | 57% | 22/76/2 | 63(36–78) | 42 | 18 | 20 | 36 | NA | ||||
| Ghorani20 | 2015 | UK | 2011.7 | 2014.5 | 18 | 44% | 56/44/0 | 60(40–77) | 10 | 1 | 3 | 15 | NA | ||||
| Nanda23 | 2015 | USA | 2010.6 | 2013.3 | 29 | 41% | 14/62/24 | 62(36–77) | 24 | 5 | 29 | 0 | NA | ||||
| Vočka29 | 2016 | Czech | 2013.1 | 2016.7 | 47 | 60% | 57/43/0 | 62(40–72) | 28 | 19 | 18 | 29 | 26 | 2 | 0 | 4 | 2 |
| Liang*26 | 2016 | China | 2014.4 | 2015.1 | 76 | 67% | 61/39/0 | 61(38–75) | NA | NA | 14 | 62 | 49 | 1 | 0 | 7 | 10 |
| Chllamma25 | 2016 | Canada | 2011.12 | 2014.7 | 66 | NA | NA | 64(28–76) | NA | NA | 22 | 44 | NA | ||||
| Takeda24 | 2015 | Japan | 2014.1 | 2015.7 | 10 | 40% | 90/10/0 | 65(59–75) | 4 | 6 | 2 | 8 | NA | ||||
| Blazer22 | 2014 | USA | 2011.1 | 2013.8 | 25 | 48% | 100%/0 | 62(40–81) | 9 | 16 | 25 | 0 | NA | ||||
| Yoshida30 | 2017 | Japan | 2014.1 | 2016.5 | 31 | 58% | 81/19/0 | 64(49–72) | 15 | 16 | 10 | 21 | 13 | 3 | 3 | 0 | 0 |
| Total | 563 | 230 | 333 | 172 | 32 | 7 | 51 | 27 | |||||||||
*There was an overlap in their study population. PS: ECOG performance status.